Global /United States /Healthcare /Biotechnology /ICCC
chevron_leftBack
ImmuCell Corp. logo

ImmuCell Corp.

ICCC
NASDAQ: ICCC Delayed
8.39USD 0.5%
As of 16 June 2026, ImmuCell Corp. has a market cap of $75.9M USD, ranking #27538 globally and #4177 in the United States. It ranks #2481 in the Healthcare sector, and #477 in the Biotechnology industry.
Global Rank
27538
Country Rank
4177
Sector Rank
2481
Industry Rank
477
Key Stats
Market Cap
$75.9MUSD
Enterprise Value
$85.59MUSD
Revenue (TTM)
$27.64MUSD
EBITDA (TTM)
$5.18MUSD
Net Income (TTM)
-$1.04MUSD
EBITDA Margin
19%
Profit Margin
-3.8%
PS Ratio
2.8
PB Ratio
2.8
EV/EBITDA
16.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
P. F. Te Boekhorst open_in_new
Employees
73
Founded
1982
IPO
30 Apr 1987
Website
immucell.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.5% 7.3% 29% 32% 36% 53%

News

Loading...

ICCC Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
ICCC
ImmuCell Corp
ISIN: US4525253062
Shares Out.:
9.047M1 Shares Float: 5.638M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
8.39 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About ImmuCell Corp.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
PE
AMGN
$182.42B
240K%
23.9
GILD
$159.92B
211K%
19.0
NTRA
$27.6B
36K%
-
$26.3B
35K%
20.0
$25.03B
33K%
20.4
MRNA
$18.13B
24K%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
ARGX
$47.89B
41.39B EUR
63K%
39.9
$45.02B
68.19T KRW
59K%
35.5
CSL
$42.64B
60.27B AUD
56K%
29.3
LONN
$42.46B
33.71B CHF
56K%
37.2
068270
$28.23B
42.76T KRW
37K%
43.8
BNTX
$25.69B
34K%
-
chevron_leftBack